Aterian, Inc. Reports Significant Earnings Miss and Rising Short Interest
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Aterian, Inc. reported earnings per share of ($0.43) for the quarter, missing the consensus estimate of ($0.17) by ($0.26). The company also reported revenue of $0.01 million, significantly below the consensus estimate of $20.30 million. As of September 15th, short interest in Aterian, Inc. totaled 826,049 shares, representing a 281.9% increase from the August 31st total.
From themarketsdaily.com
Why it matters
The company reported a negative net margin of 49.30% and a negative return on equity of 92.04%. Market analysis shows the stock currently holds a consensus rating of “Sell,” following recent research notes from Weiss Ratings and Wall Street Zen.
From themarketsdaily.com
Who's involved
- MarketBeatProvides market data and reports on Aterian, Inc.'s stock performance
- NasdaqThe stock exchange where Aterian, Inc. is listed
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Nasdaq
American fully electronic stock exchange
Related events
- Atea Pharmaceuticals is trading on the Nasdaq exchange, and MarketBeat and Morgan Stanley are providing research reports on the company's stock.
- MarketBeat reports on Rackspace Technology, a company whose stock is listed on the Nasdaq exchange.
- MarketBeat reports on stocks listed on Nasdaq, specifically mentioning The RMR Group which provides services in the United States.
- IM Cannabis, a company headquartered in Israel, utilizes MarketBeat for consensus ratings and trades on the Nasdaq stock exchange.
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.